Alpine Global Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Alpine Global Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15,400	Closed	-$1.75K	–	258
2023 Q2	$1.75K	Sell	15,400 -400	-3%	-$32	﹤0.01%	197
2023 Q1	$632	Sell	15,800 -2,400	-13%	-$186	﹤0.01%	122
2022 Q4	$1K	Sell	18,200 -41,828	-70%	-$1.57K	﹤0.01%	467
2022 Q3	$3K	Buy	60,028 +3,350	+6%	+$202	﹤0.01%	320
2022 Q2	$5K	Buy	56,678 +14,850	+36%	+$3.29K	﹤0.01%	371
2022 Q1	$15	Buy	41,828 +16,628	+66%	+$7.33K	﹤0.01%	373
2021 Q4	$13K	Buy	+25,200	New	+$14.2K	﹤0.01%	740

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Alpine Global Management's CLDI.WS Position: Q3 2023 in Review

Alpine Global Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q3 2023, closing a stake of 15,400 shares — an estimated $1.75K sold.

Alpine Global Management first reported a position in CLDI.WS in Q4 2021 and held it in 7 quarters. The position peaked at $13K in Q4 2021. 21 funds tracked by Wall St. Rank hold CLDI.WS as of Q3 2023.

Alpine Global Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q3 2023 after selling out during the quarter.
Alpine Global Management sold 15,400 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q3 2023, an estimated $1.75K.
Alpine Global Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 7 quarters.
Alpine Global Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $13K in Q4 2021.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q3 2023.

Based on Alpine Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.